Olema Pharmaceuticals (OLMA) recently reported initial Phase 1 data for its KAT6 inhibitor OP-3136, highlighting acceptable tolerability and tumor shrinkage in advanced solid tumors, including several partial responses that keep attention on the early pipeline.

Olema’s latest OP-3136 data and ongoing conference visibility come after a sharp reset in sentiment, with the share price down 44% year to date but a very large 1 year total shareholder return that signals earlier enthusiasm is now moderating.

If this kind of early stage oncology story interests you, it can be useful to compare it with other healthcare stocks using a dedicated screener for 33 healthcare AI stocks

With Olema’s share price down 44% year to date but showing a very large 1 year total return and trading at a big discount to some analyst targets, investors now have to ask: is there a buying opportunity here, or is the market already pricing in future growth?

DCF Points To A Much Higher Fair Value: Is The Gap Excessive?

Olema closed at $14.06, while the SWS DCF model estimates the future cash flow value at $183.53, indicating a very large discount at the current share price.

The SWS DCF model projects Olema’s potential future cash flows and then discounts them back to today using a required return. This produces a single fair value estimate per share. This approach can be useful for a clinical stage biotech where traditional earnings based metrics are less meaningful, because the focus is on future commercialisation rather than current revenue.

For a company like Olema, with no reported revenue and a reported loss of $185.151m, anchoring on cash flow potential rather than current income helps frame how dependent the valuation is on successful development of palazestrant and OP-3136. The wide gap between the DCF estimate and the current $14.06 price highlights how differently the model and the market are currently weighting those long term outcomes.

Result: DCF Fair value of $183.53 (UNDERVALUED)

However, you also have to weigh real risks, including Olema’s lack of revenue, the US$185.151m net loss and clinical uncertainty around palazestrant and OP-3136.

Another View: What The P/B Ratio Is Saying

On book value, Olema looks less extreme than the SWS DCF model suggests. The stock trades on a P/B of 2.6x, slightly richer than the US Biotechs industry average of 2.4x, yet well below a peer average of 14.7x. That mix hints at both valuation risk and potential upside if sentiment swings back toward higher peer style multiples.

Investors weighing the DCF signal against these book value comparisons may want to ask which crowd will prove more accurate: the cash flow modellers, or the market pricing similar stocks today.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Olema Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of cautious optimism and clear risk feels familiar, now is a good time to look through the numbers yourself, weigh the trade offs, and see how the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

Once you have formed a view on Olema, widen your opportunity set by checking other stocks that fit different risk and return profiles using focused screeners.

• Target potential bargains by reviewing companies flagged as 53 high quality undervalued stocks that combine attractive pricing with stronger fundamentals.
• Prioritise resilience by scanning 66 resilient stocks with low risk scores if you want businesses with more stable risk profiles.
• Get ahead of the crowd by searching screener containing 20 high quality undiscovered gems that could still be flying under most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.